腺苷1型受体在肾脏疾病中的研究进展

doi:10.3969/j.issn.1006-7795.2024.03.025

摘要/Abstract

摘要： 腺苷在细胞内、外具有多种信号转导功能，通过激活不同类型的腺苷受体发挥生物学作用。腺苷1型受体作为高亲和力受体，在肾脏组织中广泛表达，参与炎症、免疫、血流动力学调节。目前，糖尿病肾病、高血压肾病、急性肾损伤等常见肾脏疾病的发病机制尚未完全明确。腺苷1型受体参与了糖尿病肾病、肾脏缺血再灌注损伤、造影剂肾病的等多种肾脏疾病的病理过程。本文针对腺苷1型受体在肾脏疾病中的研究进展进行综述。

关键词: 腺苷1型受体, 肾脏疾病, 发病机制

Abstract: Adenosine plays a biological role of signal transduction inside and outside cells by activating different types of adenosine receptors. Adenosine type 1 receptor, as high affinity receptor, is widely expressed in renal tissues, involved in inflammation, immunity, and hemodynamic regulation. At present, the pathogenesis of common kidney disease such as diabetic nephropathy, hypertensive nephropathy and acute kidney injury have not been fully defined. It has been confirmed that adenosine type 1 receptor is involved in the pathological process of various renal diseases such as diabetic nephropathy, renal ischemia-reperfusion injury and contrast nephropathy. We reviewed the advance in researches of adenosine type 1 receptor in renal disease.

Key words: adenosine type 1 recepto, renal diseases, pathogenesis

中图分类号:

白雨, 田东丽. 腺苷1型受体在肾脏疾病中的研究进展[J]. 首都医科大学学报, 2024, 45(3): 543-547.

Bai Yu, Tian Dongli. Advance on role of adenosine type 1 receptor in renal diseases[J]. Journal of Capital Medical University, 2024, 45(3): 543-547.

参考文献

［1］ Peleli M, Carlstrom M. Adenosine signaling in diabetes mellitus and associated cardiovascular and renal complications［J］. Mol Aspects Med, 2017, 55: 62－74.
［2］ Babich V, Vadnagara K, Di Sole F. Adenosine A2A receptor blocks the a 1 receptor inhibition of renal Na+ transport and oxygen consumption［J］. J Cell Physiol, 2019, 234(8): 13917－13930.
［3］ Roberts V S, Cowan P J, Alexander S I, et al. The role of adenosine receptors A2A and A2B signaling in renal fibrosis［J］. Kidney Int, 2014, 86(4): 685－692.
［4］ Peleli M, Hezel M, Zollbrecht C, et al. In adenosine A2B knockouts acute treatment with inorganic nitrate improves glucose disposal, oxidative stress, and AMPK signaling in the liver［J］. Front Physiol, 2015, 6: 222.
［5］ Layland J, Carrick D, Lee M, et al. Adenosine: physiology, pharmacology, and clinical applications［J］. JACC Cardiovasc Interv, 2014, 7(6): 581－591.
［6］ Carlström M, Wilcox C S, Arendshorst W J. Renal autoregulation in health and disease［J］. Physiol Rev, 2015, 95(2): 405－511.
［7］ Antonioli L, Blandizzi C, Csóka B, et al. Adenosine signalling in diabetes mellitus—pathophysiology and therapeutic considerations［J］. Nat Rev Endocrinol, 2015, 11(4): 228－241.
［8］ Antonioli L, Blandizzi C, Pacher P, et al. Immunity, inflammation and cancer: a leading role for adenosine［J］. Nat Rev Cancer, 2013, 13(12): 842－857.
［9］ Cekic C, Linden J. Purinergic regulation of the immune system［J］. Nat Rev Immunol, 2016, 16(3): 177－192.
［10］ Vallon V, Osswald H. Adenosine receptors and the kidney［J］. Handb Exp Pharmacol, 2009(193): 443－470.
［11］ Rieg T, Vallon V. ATP and adenosine in the local regulation of water transport and homeostasis by the kidney［J］. Am J Physiol Regul Integr Comp Physiol, 2009, 296(2): R419-R427.
［12］ Ortiz-Capisano M C, Atchison D K, Harding P, et al. Adenosine inhibits renin release from juxtaglomerular cells via an A1 receptor-TRPC-mediated pathway［J］. Am J Physiol Renal Physiol, 2013, 305(8): F1209-F1219.
［13］ Pandey S, Aggarwal D, Gupta K, et al. “Adenosine an old player with new possibilities in kidney diseases”: preclinical evidences and clinical perspectives［J］. Life Sci, 2021, 265: 118834.
［14］ Olivera A, Lamas S, Rodriguez-Puyol D, et al. Adenosine induces mesangial cell contraction by an A1-type receptor［J］. Kidney Int, 1989, 35(6): 1300－1305.
［15］ MacLaughlin M, Martinez-Salgado C, Eleno N, et al. Adenosine activates mesangial cell proliferation［J］. Cell Signal, 1997, 9(1): 59－63.
［16］ Takeda M, Yoshitomi K, Imai M. Regulation of Na(+)－3HCO^－₃ cotransport in rabbit proximal convoluted tubule via adenosine A1 receptor［J］. Am J Physiol, 1993, 265(4 Pt 2): F511-F519.
［17］ Edwards R M, Spielman W S. Adenosine a1 receptor-mediated inhibition of vasopressin action in inner medullary collecting duct［J］. Am J Physiol, 1994, 266(5 Pt 2): F791-F796.
［18］ Shimizu M, Furuichi K, Wada T. Epidemiology and pathogenesis of diabetic nephropathy［J］. Nihon Jinzo Gakkai Shi, 2018, 59(2): 43－49.
［19］ Meza Letelier C E, San Martín Ojeda C A, Ruiz Provoste J J, et al. Pathophysiology of diabetic nephropathy: a literature review［J］. Medwave, 2017, 17(1): e6839.
［20］ Wolf G, Ziyadeh F N. Cellular and molecular mechanisms of proteinuria in diabetic nephropathy［J］. Nephron Physiol, 2007, 106(2): p26-p31.
［21］ Stitt-Cavanagh E, MacLeod L, Kennedy C. The podocyte in diabetic kidney disease［J］. Scientific World Journal, 2009, 9: 1127－1139.
［22］ Faulhaber-Walter R, Jiang L P, Mizel D, et al. Podocyte density and albuminuria in aging diabetic Ins2± mice with or without adenosine a1 receptor signaling［J］. Int J Nephrol Renovasc Dis, 2020, 13: 19－26.
［23］ Tesch G H. Diabetic nephropathy-is this an immune disorder?［J］. Clin Sci (Lond), 2017, 131(16): 2183－2199.
［24］ Lim A K H, Tesch G H. Inflammation in diabetic nephropathy［J］. Mediators Inflamm, 2012, 2012: 146154.
［25］ Tian D, Shi X, Zhao Y, et al. The effect of A1 adenosine receptor in diabetic megalin loss with caspase-1/IL18 signaling［J］. Diabetes Metab Syndr Obes, 2019, 12: 1583－1596.
［26］ Rossier B C, Bochud M, Devuyst O. The hypertension pandemic: an evolutionary perspective［J］. Physiology (Bethesda), 2017, 32(2): 112－125.
［27］ Nishiyama A, Inscho E W, Navar L G. Interactions of adenosine A1 and A2a receptors on renal microvascular reactivity［J］. Am J Physiol Renal Physiol, 2001, 280(3): F406-F414.
［28］ Wierema T K A, Houben A J H M, Kroon A A, et al. Mechanisms of adenosine-induced renal vasodilatation in hypertensive patients［J］. J Hypertens, 2005, 23(9): 1731－1736.
［29］ Aki Y, Nishiyama A, Miyatake A, et al. Role of adenosine A(1) receptor in angiotensin II- and norepinephrine-induced renal vasoconstriction［J］. J Pharmacol Exp Ther, 2002, 303(1): 117－123.
［30］ Bauerle J D, Grenz A, Kim J H, et al. Adenosine generation and signaling during acute kidney injury［J］. J Am Soc Nephrol, 2011, 22(1): 14－20.
［31］ Hoste E A, Schurgers M. Epidemiology of acute kidney injury: how big is the problem?［J］. Crit Care Med, 2008, 36(4 Suppl): S146-S151.
［32］ Barrera-Chimal J, Pérez-Villalva R, Rodríguez-Romo R, et al. Spironolactone prevents chronic kidney disease caused by ischemic acute kidney injury［J］. Kidney Int, 2013, 83(1): 93－103.
［33］ Awad A S, Rouse M, Huang L P, et al. Compartmentalization of neutrophils in the kidney and lung following acute ischemic kidney injury［J］. Kidney Int, 2009, 75(7): 689－698.
［34］ Malek M, Nematbakhsh M. Renal ischemia/reperfusion injury; from pathophysiology to treatment［J］. J Renal Inj Prev, 2015, 4(2): 20－27.
［35］ Lee H T, Gallos G, Nasr S H, et al. A1 adenosine receptor activation inhibits inflammation, necrosis, and apoptosis after renal ischemia-reperfusion injury in mice［J］. J Am Soc Nephrol, 2004, 15(1): 102－111.
［36］ Joo J D, Kim M, Horst P, et al. Acute and delayed renal protection against renal ischemia and reperfusion injury with A1 adenosine receptors［J］. Am J Physiol Renal Physiol, 2007, 293(6): F1847-F1857.
［37］ Park S W, Kim M, Kim J Y, et al. Proximal tubule sphingosine kinase-1 has a critical role in A1 adenosine receptor-mediated renal protection from ischemia［J］. Kidney Int, 2012, 82(8): 878－891.
［38］ Xiong B, Li M, Xiang S L, et al. A1AR-mediated renal protection against ischemia/reperfusion injury is dependent on HSP27 induction［J］. Int Urol Nephrol, 2018, 50(7): 1355－1363.
［39］ Najafi H, Owji S M, Kamali-Sarvestani E, et al. A1 -adenosine receptor activation has biphasic roles in development of acute kidney injury at 4 and 24 h of reperfusion following ischaemia in rats［J］. Exp Physiol, 2016, 101(7): 913－931.
［40］ Bhat S G, Mishra S, Mei Y, et al. Cisplatin up-regulates the adenosine A(1) receptor in the rat kidney［J］. Eur J Pharmacol, 2002, 442(3): 251－264.
［41］ Gill A, Wortham K, Costa D, et al. Protective effect of tonapofylline (BG9928), an adenosine A1 receptor antagonist, against cisplatin-induced acute kidney injury in rats［J］. Am J Nephrol, 2009, 30(6): 521－526.
［42］ Knight R J, Collis M G, Yates M S, et al. Amelioration of cisplatin-induced acute renal failure with 8-cyclopentyl-1,3-dipropylxanthine［J］. Br J Pharmacol, 1991, 104(4): 1062－1068.
［43］ Yao K, Kusaka H, Sato K, et al. Protective effects of KW-3902, a novel adenosine A1-receptor antagonist, against gentamicin-induced acute renal failure in rats［J］. Jpn J Pharmacol, 1994, 65(2): 167－170.
［44］ Asif A, Epstein M. Prevention of radiocontrast-induced nephropathy［J］. Am J Kidney Dis, 2004, 44(1): 12－24.
［45］ Lee H T, Jan M, Bae S C, et al. A1 adenosine receptor knockout mice are protected against acute radiocontrast nephropathy in vivo［J］. Am J Physiol Renal Physiol, 2006, 290(6): F1367－F1375.